Clinical Trials Logo
  1. Home
  2. Newly Diagnosed Glioblastoma
  3. NCT05380349

Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma

Newly Diagnosed Glioblastoma Clinical Trial

Official title:
A Phase 1 Study of Combination Drug Therapy Based on Personalized Cancer Stem Cell (CSC) High-Throughput Drug Screening (HTS) With Standard of Care for Newly Diagnosed Glioblastoma

Clinical Trial Summary

Proposed treatment of subjects with newly diagnosed glioblastoma with novel personalized drug regimens identified to be effective in vitro using cancer stem cells derived from their individual tumors, alongside standard of care radiation and TMZ.

Clinical Trial Description

A panel of FDA approved drugs will be tested by high throughput screening, which is CLIA certified allowing for clinical decisions based on the results, to identify a combination of up to 3 drug candidates for treating individual patients. Lead candidates will be evaluated by pharmacists and a team of physicians, to confirm that prescribed drugs do not utilize pharmacological/ metabolic pathways that are known to increase the likelihood of toxicity, prior to initiating treatment. Investigational drug therapy, targeting CSCs, will be initiated alongside standard of care chemoradiation with TMZ. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05380349
Study type Interventional
Source Swedish Medical Center
Contact Charles S Cobbs, M.D.
Phone 206-320-2300
Email charles.cobbs@swedish.org
Status Recruiting
Phase Early Phase 1
Start date April 19, 2024
Completion date December 2027
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03899857 - Pembrolizumab for Newly Diagnosed Glioblastoma Phase 2
Active, not recruiting NCT05163080 - SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) Phase 2
Recruiting NCT04474353 - Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma Phase 1
Recruiting NCT05235737 - The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab Phase 4
Recruiting NCT04840069 - Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma Phase 2
Active, not recruiting NCT03400917 - Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma Phase 2
Completed NCT03619239 - Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma Phase 1
Completed NCT03345095 - A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma Phase 3
Recruiting NCT04478279 - A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05864534 - Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma Phase 2
Not yet recruiting NCT04967690 - A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM Phase 1
Active, not recruiting NCT04600817 - A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT) Phase 2
Active, not recruiting NCT03782415 - Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma Phase 1/Phase 2
Recruiting NCT04477200 - Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma Phase 1
Withdrawn NCT04065087 - Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma Phase 1/Phase 2